Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
PTCT
PTCT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest PTCT ETF News Today | Earnings, Events & Price Alerts
PTCT News
Palo Alto Investors Increases Stake in PTC Therapeutics
1d ago
Fool
PTC Therapeutics Announces Upcoming Conference Schedule
Feb 23 2026
PRnewswire
PTC Therapeutics Q4 2025 Earnings Call Highlights
Feb 20 2026
seekingalpha
Phenylketonuria Treatment Market Outlook Analysis
Feb 18 2026
Newsfilter
PTC Therapeutics Withdraws New Drug Application for Translarna
Feb 13 2026
Benzinga
PTC Therapeutics Withdraws NDA Resubmission for Translarna
Feb 12 2026
seekingalpha
PTC Therapeutics Withdraws NDA for Translarna Due to FDA Feedback
Feb 12 2026
PRnewswire
PTC Therapeutics Withdraws NDA for Translarna Due to FDA Feedback
Feb 12 2026
Newsfilter
Rare Disease Biotechs Show Strong 2025 Performance with Cashflow and R&D Expansion
Jan 14 2026
Yahoo Finance
PTC Therapeutics Launches Sephience™ with Q4 Revenue of $92.5M
Jan 12 2026
PRnewswire
PTC Therapeutics Grants 300 RSUs to Attract New Employee
Jan 08 2026
Newsfilter
PTC Therapeutics Grants 300 RSUs to Attract New Employee
Jan 08 2026
PRnewswire
Royalty Pharma Acquires Evrysdi Royalty for $240 Million Upfront
Dec 31 2025
Benzinga
Earnings Warning Season is Here: Strategies to Benefit from Others' Struggles.
Dec 31 2025
Barron's
Royalty Pharma Acquires Remaining Evrysdi Royalty Interest for $240M Upfront
Dec 30 2025
NASDAQ.COM
Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway
Dec 26 2025
NASDAQ.COM
Show More News
